DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/7b89d8/dyslipidemia_pip) has announced the addition of GlobalData 's new report "Dyslipidemia Pipeline Assessment and Market Forecasts to 2016" to their offering.
Dyslipidemia - Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
The Dyslipidemia Market is Forecast to Decline until 2016
The authors estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. It is expected to decline at a compound annual growth rate (CAGR) of approximately 3.7% from $34.4 billion in 2009 to $26.3 billion by 2016. Although the cardiovascular market expanded considerably from 2004 to 2008, growth in the seven major markets is expected to slow down from 2013 onwards. The decline in sales during this period will be due to the expiry of many leading brands patents. Pfizers Lipitor, a major blockbuster in the dyslipidemia market, is set to expire in 2011. Following the expiry of Lipitors patent, Simcor and Trilipixs patents will also expire in 2011. The patents of Zetia, Vyotrin, Lescol, Livalo and Lovaza are set to expire between 2012 and 2014. The market growth will be sustained by the launch of major new products with safety and convenience advantages such as once-daily administration and combinational therapies. The New Drug Application for Cetriad, being co-developed by AstraZeneca and Abbott Laboratories, has been filed with the US FDA and is currently the most anticipated drug in the pipeline.
Global Dyslipidemia Therapeutics Market, Revenue ($bn), 20012016
Competition in the Dyslipidemia Market is Strong
The authors found that the current competition in the dyslipidemia market is becoming intense due to the increased entry of combinational therapies and the use of statins, fibrates, niacin and omega-3 fatty acid derivatives as antidyslipidemic agents. It projects that Lipitor, Trilipix and Simcor will be the leading competitors in the global dyslipidemia market. Pfizer, Abbott Laboratories, AstraZeneca and Merck will continue to be the market leaders until the patents on their drugs expire in between 2011 and 2014. The market is set to shrink following the expiry of Pfizers Lipitor. Also Simcor, Trilipix, Vyotrin, Zetia, Lescol, Lovaza and Livalo are all set to expire between 2011 and 2014. The dyslipidemia market is expected to show decline due to patent expiries in the near future.
Key Topics Covered:
- 1.1 List of Tables
- 2 Global Dyslipidemia Market: Market Characterization
- 3 Dyslipidemia Market: Competitive Assessment
- 4 Dyslipidemia Market: Pipeline Assessment
- 5 Dyslipidemia Market: Implications for Future Market Competition
- 6 Dyslipidemia Market: Future Players in the Dyslipidemia Market
- 7 Dyslipidemia Market: Appendix
- AstraZeneca PLC
- Abbott Laboratories
- Merck & Co.
- Aegerion Pharmaceuticals, Inc
- Amarin Corporation Plc
- Pfizer Inc.
For more information visit http://www.researchandmarkets.com/research/7b89d8/dyslipidemia_pip
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Pharmaceutical